Home > Insider Trading > Filing (0001209191-11-021854)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1100962	Endo Pharmaceuticals Holdings Inc	ENDP	Pharmaceutical Preparations (2834)	134022871

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1179357	B Caroline Manogue	100 Endo Boulevard Chadds Ford PA 19317	Exec. V.p., Clo & Secy	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock, Par Value, $.01 Per Share	Acquisiton	2011-04-05	35,000	$15.24	35,000	No	4	M	Direct
Common Stock, Par Value, $.01 Per Share	Disposition	2011-04-05	35,000	$39.90	0	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	2000 Stock Incentive Plan Stock Options (NQ)	Disposition	2011-04-05	35,000	$0.00	35,000	$15.24

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
35,000		2013-08-05	No	4	M	Direct

Footnotes

On December 3, 2010, Ms. Manogue placed 70,000 of the shares underlying her stock options into a 10b5-1 pre-set selling program until December 31, 2011 (the "Manogue Pre-Set Selling Program"). The options exercised and the shares sold here were sold pursuant to the Manogue Pre-Set Selling Program, which leaves 35,000 shares (underlying options) in the Manogue Pre-Set Selling Program.
This represents the price at which Ms. Manogue's common shares were sold on April 5, 2011.
Ms. Manogues's stock options that were granted under the 2000 Stock Incentive Plan on August 5, 2003, are generally exercisable 25% per year on each of August 5, 2004, August 5, 2005, August 5, 2006 and August 5, 2007.
These securities were granted to Ms. Manogue in 2003 in consideration of her services as the Executive Vice President, Chief Legal Officer & Secretary of Endo Pharmaceuticals Holdings Inc.